Zusammenfassung
Es ist nicht überraschend, daß bei Niereninsuffizienz die renale Elimination der Arzneimittel, die normalerweise zu einem bedeutsamen Teil über die Nieren ausgeschieden werden, abnimmt. Das gilt auch für die Antihypertensiva.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
Literatur
Øie S, Levy G (1975) Relationship between renal function and elimination kinetics of pindolol in man. Eur J Clin Pharmacol 9:115–116
Thompson FD, Joekes AM, Foulkes DM (1972) Pharmacodynamics of propranolol in renal failure. Br Med J 2:434–436
Zsotér TT, Johnson GE, DeVeber GA, Paul H (1973) Excretion and metabolism of reserpine in renal failure. Clin Pharmacol Ther 14:325–330
Chau NP, Weiss YA, Safar ME, Lavene DE, Georges DR, Milliez PL (1977) Pindolol availability in hypertensive patients with normal and impaired renal function. Clin Pharmacol Ther 22:505–510
Rane A, Villeneuve JP, Stone WJ, Nies AS, Wilkinson GR, Branch RA (1978) Plasma binding and disposition of furosemide in the nephrotic syndrome and in uremia. Clin Pharmacol Ther 24:199–207
Rahn KH (1973) The influence of renal function on plasma levels, urinary excretion, metabolism, and antihypertensive effect of guanethidine (Ismelin) in man. Clin Nephrol 1:14–23
Maitre L, Staehelin M, Brunner H (1971) Antihypertensive and noradrenaline depleting effects of guanethidine metabolites. J Pharm Pharmacol 23:327–331
Seiler KU, Hunecke R, Meyer GJ (1977) Pharmakokinetik von Propranolol und Clonidin bei Patienten während chronisch intermittierender Hämodialysebehandlung. Verh Dtsch Ges Inn Med 83:1712–1714
Schulz V, Döhring W, Rathsack P (1978) Thiozyanat-Vergiftung bei der antihypertensiven Therapie mit Natriumnitroprussid. Klin Wochenschr 56:355–361
Talseth T (1976) Studies on hydralazine. II. Elimination rate and steady-state concentration in patients with impaired renal function. Eur J Clin Pharmacol 10:311–317
Koch-Weser J (1976) Diazoxide. N Engl J Med 294:1271–1274
Huang CM, Atkinson AJ Jr, Levin M, Levin NW, Quintanilla A (1974) Pharmacokinetics of furosemide in advanced renal failure. Clin Pharmacol Ther 16:659–666
Schrader K, Brass H, Renner D (1971) Zur Pharmakokinetik von Alpha-Methyldopa bei Niereninsuffizienz. Klin Wochenschr 49:1329–1334
Stenbaek Ø, Myhre E, Brodwall EK, Hansen T (1972) Hypotensive effect of methyldopa in renal failure associated with hypertension. Acta Med Scand 191:333–337
McAinsh J (1977) Clinical pharmacokinetics of atenolol. Postgrad Med J 53:Suppl. 3, 74–78
Tjandramaga TB, Thomas J, Verbeeck R, Verbesselt R, Verberckmoes R, Schepper PJ (1976) The effect of end-stage renal failure and haemodia-lysis on the elimination of Sotalol. Br J Clin Pharmacol 3:259–265
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1980 Springer-Verlag Berlin Heidelberg
About this paper
Cite this paper
Rahn, K.H. (1980). Pharmakokinetik von Antihypertensiva bei Niereninsuffizienz. In: Heidland, A., Wetzels, E. (eds) Pharmakotherapie bei Niereninsuffizienz. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-67676-5_9
Download citation
DOI: https://doi.org/10.1007/978-3-642-67676-5_9
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-10101-7
Online ISBN: 978-3-642-67676-5
eBook Packages: Springer Book Archive